Hepacivirus

• 

  Subject Areas on Research

  • A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE Study. 
  • A highly sensitive and specific enzyme-linked immunosorbent assay of antibodies to hepatitis C virus. 
  • A laboratory-adapted HCV JFH-1 strain is sensitive to neutralization and can gradually escape under the selection pressure of neutralizing human plasma. 
  • A link between leptin and steatosis in chronic hepatitis C? Time to weigh up the fats. 
  • A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial. 
  • A multicenter study of recombinant human interleukin 12 for the treatment of chronic hepatitis C virus infection in patients nonresponsive to previous therapy. 
  • A phase I trial of an antisense inhibitor of hepatitis C virus (ISIS 14803), administered to chronic hepatitis C patients. 
  • A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection. 
  • A small yeast RNA blocks hepatitis C virus internal ribosome entry site (HCV IRES)-mediated translation and inhibits replication of a chimeric poliovirus under translational control of the HCV IRES element. 
  • Activation and evasion of antiviral innate immunity by hepatitis C virus. 
  • Acute HCV: the early bird catches the virus. 
  • Addressing Hepatitis C in the American Incarcerated Population: Strategies for Nationwide Elimination. 
  • Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. 
  • Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 2 or 3. 
  • Altered m6A Modification of Specific Cellular Transcripts Affects Flaviviridae Infection. 
  • An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. 
  • An independent and prospective comparison of two commercial fibrosis marker panels (HCV FibroSURE and FIBROSpect II) during albinterferon alfa-2b combination therapy for chronic hepatitis C. 
  • An interrupted time series evaluation of a hepatitis C intervention for persons with HIV. 
  • Antibodies to hepatitis B virus and hepatitis C virus in alcoholic hepatitis and cirrhosis: their prevalence and clinical relevance. The VA Cooperative Study Group (No. 119). 
  • Antibody-selected mimics of hepatitis C virus hypervariable region 1 activate both primary and memory Th lymphocytes. 
  • Antisense inhibitors, ribozymes, and siRNAs. 
  • Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients. 
  • Approach to the treatment-naïve patient with HCV genotype 1 infection. 
  • Association of CYP2B6 Single-Nucleotide Polymorphisms Altering Efavirenz Metabolism With Hepatitis C Virus (HCV) Treatment Relapse Among Human Immunodeficiency Virus/HCV-Coinfected African Americans Receiving Ledipasvir/Sofosbuvir in the ION-4 Trial. 
  • Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. 
  • Asymmetric Synthesis of 2'-C -Methyl-4'-selenonucleosides as Anti-Hepatitis C Virus Agents. 
  • Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null response. 
  • Boceprevir for untreated chronic HCV genotype 1 infection. 
  • Cardiac dysfunction associated with a nucleotide polymerase inhibitor for treatment of hepatitis C. 
  • Characterization of the emerging HIV type 1 and HCV epidemics among injecting drug users in Dushanbe, Tajikistan. 
  • Clinical hepatitis after transplantation of hepatitis C virus-positive kidneys: HLA-DR3 as a risk factor for the development of posttransplant hepatitis. 
  • Clinical trial: interferon alpha-2b continuous long-term therapy vs. repeated 24-week cycles for re-treating chronic hepatitis C. 
  • Clinical utility of total HCV core antigen quantification: a new indirect marker of HCV replication. 
  • Commentary: The Field Moves Forward. 
  • Community-based HCV screening: knowledge and attitudes in a high risk urban population. 
  • Comparisons of CD8+ T cells specific for human immunodeficiency virus, hepatitis C virus, and cytomegalovirus reveal differences in frequency, immunodominance, phenotype, and interleukin-2 responsiveness. 
  • Control of innate immune signaling and membrane targeting by the Hepatitis C virus NS3/4A protease are governed by the NS3 helix α0. 
  • Convergent evolution of escape from hepaciviral antagonism in primates. 
  • Cooperation between the Hepatitis C Virus p7 and NS5B Proteins Enhances Virion Infectivity. 
  • Coordination, Cost, and Changing Epidemiology-Considerations in the Hepatitis C Care Cascade. 
  • Correlation of the tight junction-like distribution of Claudin-1 to the cellular tropism of hepatitis C virus. 
  • Cost-effectiveness of truncated therapy for hepatitis C based on rapid virologic response. 
  • Curing hepatitis C virus (HCV) after organ transplantation: Increased risk of rejection following HCV elimination. 
  • Current therapies for chronic hepatitis C. Drug combination achieves sustained response in more than half of patients. 
  • Cyclophilin B escorts the hepatitis C virus RNA polymerase: a viral achilles heel? 
  • Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis. 
  • Definition and management of anemia in patients infected with hepatitis C virus. 
  • Determining the Incidence of Hepatitis C Virus Infection in Populations: An Important Tool for Epidemic Control. 
  • Dialysis-requiring acute kidney injury among hospitalized adults with documented hepatitis C Virus infection: a nationwide inpatient sample analysis. 
  • Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. 
  • Differential prevalence and geographic distribution of hepatitis C virus genotypes in acute and chronic hepatitis C patients in Vietnam. 
  • Direct acting antivirals for the treatment of hepatitis C in ethnic minority populations. 
  • Directly acting antivirals for the treatment of patients with hepatitis C infection: a clinical development update addressing key future challenges. 
  • Domain 3 of hepatitis C virus core protein is sufficient for intracellular lipid accumulation. 
  • Donor-derived hepatitis C in the era of increasing intravenous drug use: A report of the Disease Transmission Advisory Committee. 
  • Donor-derived hepatitis C transmission from NAT negative donors-Still an unexpected event! 
  • Drug resistance and HCV coinfection in former blood donors infected with HIV type 1 in China. 
  • Dysregulation of distal cholesterol biosynthesis in association with relapse and advanced disease in CHC genotype 2 and 3 treated with sofosbuvir and ribavirin. 
  • Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: impaired viral kinetics and therapeutic response. 
  • Early experience with the use of hepatitis C antibody-positive, nucleic acid testing-negative donors in lung transplantation. 
  • Early prediction of sustained virological response at day 3 of treatment with albinterferon-alpha-2b in patients with genotype 2/3 chronic hepatitis C. 
  • Economic evaluation of direct-acting antiviral therapy in chronic hepatitis C. 
  • Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1-infected patients. 
  • Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection. 
  • Efficacy and safety of simeprevir and sofosbuvir with and without ribavirin in subjects with recurrent genotype 1 hepatitis C postorthotopic liver transplant: the randomized GALAXY study. 
  • Efficacy of Sofosbuvir Plus Ribavirin in Veterans With Hepatitis C Virus Genotype 2 Infection, Compensated Cirrhosis, and Multiple Comorbidities. 
  • Efforts at the Frontlines: Implementing a Hepatitis C Testing and Linkage-to-Care Program at the Local Public Health Level. 
  • Eight Weeks of Treatment With Glecaprevir/Pibrentasvir Is Safe and Efficacious in an Integrated Analysis of Treatment-Naïve Patients With Hepatitis C Virus Infection. 
  • Elucidation of hepatitis C virus transmission and early diversification by single genome sequencing. 
  • Emerging therapies in hepatitis C: dawn of the era of the direct-acting antivirals. 
  • Evaluation for Fibrosis After Cure of Hepatitis C-Reply. 
  • Evidence of viral adaptation to HLA class I-restricted immune pressure in chronic hepatitis C virus infection. 
  • Expanding the use of hepatitis C-viremic kidney donors. 
  • Facilitating engagement of persons with opioid use disorder in treatment for hepatitis C virus infection via telemedicine: Stories of onsite case managers. 
  • FibroSURE and FibroScan in relation to treatment response in chronic hepatitis C virus. 
  • Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection. 
  • Future trends in managing hepatitis C. 
  • Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. 
  • Genotype 3 Infection: The Last Stand of Hepatitis C Virus. 
  • Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis. 
  • HIV/HCV-coinfected natural viral suppressors have better virologic responses to PEG-IFN and ribavirin than ARV-treated HIV/HCV patients. 
  • Hepatitis B and C viruses in infants and young children. 
  • Hepatitis B core antibody positive donors as a safe and effective therapeutic option to increase available organs for lung transplantation. 
  • Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. 
  • Hepatitis C Virus Elimination in the Human Immunodeficiency Virus-Coinfected Population: Leveraging the Existing Human Immunodeficiency Virus Infrastructure. 
  • Hepatitis C Virus Infection Is Inhibited by a Noncanonical Antiviral Signaling Pathway Targeted by NS3-NS4A. 
  • Hepatitis C Virus Postexposure Prophylaxis in the Healthcare Worker: Why Direct-Acting Antivirals Don't Change a Thing. 
  • Hepatitis C Virus Treatment Delivered via Telemedicine to Persons With Opioid Use Disorder. 
  • Hepatitis C Virus Treatment: Is It Possible To Cure All Hepatitis C Virus Patients? 
  • Hepatitis C Virus, Inflammation, and Cellular Aging: Turning Back Time. 
  • Hepatitis C and steatosis. 
  • Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. 
  • Hepatitis C treatment among racial and ethnic groups in the IDEAL trial. 
  • Hepatitis C trials that combine investigational agents with pegylated interferon should be stratified by interleukin-28B genotype. 
  • Hepatitis C virus positive diffuse large B-cell lymphomas have distinct molecular features and lack BCL2 translocations. 
  • Hepatitis C virus selectively perturbs the distal cholesterol synthesis pathway in a genotype-specific manner. 
  • Hepatitis C virus seropositivity at the time of renal transplantation in the United States: associated factors and patient survival. 
  • Hepatitis C-induced hepatic allograft injury is associated with a pretransplantation elevated viral replication rate. 
  • Hepatitis-C-virus-induced microRNAs dampen interferon-mediated antiviral signaling. 
  • Human La antigen is required for the hepatitis C virus internal ribosome entry site-mediated translation. 
  • Hypervariable region 1 variant acting as TCR antagonist affects hepatitis C virus-specific CD4+ T cell repertoire by favoring CD95-mediated apoptosis. 
  • IDSA/AASLD Response to Cochrane Review on Direct-Acting Antivirals for Hepatitis C. 
  • IGHV1-69 B cell chronic lymphocytic leukemia antibodies cross-react with HIV-1 and hepatitis C virus antigens as well as intestinal commensal bacteria. 
  • IL28B in the era of direct-acting antivirals for hepatitis C. 
  • Identification and comparative analysis of hepatitis C virus-host cell protein interactions. 
  • Immunologic Change over 72 Weeks Following Raltegravir- Versus Efavirenz-Based Therapy in HIV/HCV-Coinfected Individuals in Vietnam. 
  • Impact of EGF, IL28B, and PNPLA3 polymorphisms on the outcome of allograft hepatitis C: a multicenter study. 
  • Impact of Substance Use Disorder on the Rate of Sustained Virological Response in Veterans With Chronic Hepatitis C Treated With Direct-Acting Antivirals. 
  • Importance of Hepatitis C Virus RNA Testing in Patients with Suspected Drug-Induced Liver Injury. 
  • Improved Survival After Liver Transplantation for Patients With Human Immunodeficiency Virus (HIV) and HIV/Hepatitis C Virus Coinfection in the Integrase Strand Transfer Inhibitor and Direct-Acting Antiviral Eras. 
  • Improved detection of hepatitis C virus infection by transcription-mediated amplification technology in dialysis population. 
  • Improving HCV Risk Assessment and Testing in a Federally Qualified Health Center Setting in Baltimore, Maryland. 
  • Improving Hepatitis C Identification: Technology Alone Is Not the Answer. 
  • In HIV/hepatitis C virus co-infected patients, higher 25-hydroxyvitamin D concentrations were not related to hepatitis C virus treatment responses but were associated with ritonavir use. 
  • In Reply. 
  • In the clinic. Hepatitis C. 
  • Incarceration, drug use, and infectious diseases: a syndemic still not addressed. 
  • Individualized therapy for hepatitis C infection: focus on the interleukin-28B polymorphism in directing therapy. 
  • Initial treatment for chronic hepatitis C: current therapies and their optimal dosing and duration. 
  • Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR. 
  • Insights into antiviral innate immunity revealed by studying hepatitis C virus. 
  • Interferon and ribavirin therapy does not select for resistance mutations in hepatitis C virus polymerase. 
  • Interferon gamma-1b for the treatment of fibrosis in chronic hepatitis C infection. 
  • Interleukin 28B polymorphisms are the only common genetic variants associated with low-density lipoprotein cholesterol (LDL-C) in genotype-1 chronic hepatitis C and determine the association between LDL-C and treatment response. 
  • Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. 
  • Intracellular innate immune cascades and interferon defenses that control hepatitis C virus. 
  • Kinetics of hepatitis C virus reinfection after liver transplantation. 
  • Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. 
  • Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1. 
  • Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. 
  • Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. 
  • Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. 
  • Ledipasvir/Sofosbuvir for 8 Weeks to Treat Acute Hepatitis C Virus Infections in Men With Human Immunodeficiency Virus Infections: Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1 Infected Individuals. 
  • Live donor liver transplantation with older donors: Increased long-term graft loss due to HCV recurrence. 
  • Liver transplant for hepatocellular carcinoma in the United States: Evolving trends over the last three decades. 
  • Long-term Patient-Centered Outcomes in Cirrhotic Patients With Chronic Hepatitis C After Achieving Sustained Virologic Response. 
  • Lost in translation? IL28B's discovery and the journey back to the patient. 
  • Making it happen: managed care considerations in vanquishing hepatitis C. 
  • Management of hepatitis C virus infection: the basics. 
  • Maximizing utilization of the donor pool by appropriate classification of hepatitis C antibody-positive donors. 
  • Measuring Hepatitis C Virus Envelopment by Using a Proteinase K Protection Assay. 
  • Medication Non-adherence in a Prospective, Multi-center Cohort Treated with Hepatitis C Direct-Acting Antivirals. 
  • Mitochondrial-associated endoplasmic reticulum membranes (MAM) form innate immune synapses and are targeted by hepatitis C virus. 
  • Modeling the probability of sustained virological response to therapy with pegylated interferon plus ribavirin in patients coinfected with hepatitis C virus and HIV. 
  • Molecular determinants and dynamics of hepatitis C virus secretion. 
  • Multiinstitutional Evaluation of the Liver Surface Nodularity Score on CT for Staging Liver Fibrosis and Predicting Liver-Related Events in Patients With Hepatitis C. 
  • New Treatment Options for Hepatitis C Virus Infection in End-Stage Kidney Disease: To Treat or Not to Treat. 
  • Nonalcoholic Fatty Liver Disease Risk Factors Affect Liver-Related Outcomes After Direct-Acting Antiviral Treatment for Hepatitis C. 
  • Not Achieving Sustained Viral Eradication of Hepatitis C Virus After Treatment Leads to Worsening Patient-reported Outcomes. 
  • Open-label phase 1b pilot study to assess the antiviral efficacy of simvastatin combined with sertraline in chronic hepatitis C patients. 
  • Open-label, ascending dose, prospective cohort study evaluating the antiviral efficacy of Rosuvastatin therapy in serum and lipid fractions in patients with chronic hepatitis C. 
  • Oral Combination Therapies for Hepatitis C Virus Infection: Successes, Challenges, and Unmet Needs. 
  • Osteopontin is up-regulated in chronic hepatitis C and is associated with cellular permissiveness for hepatitis C virus replication. 
  • Overcoming barriers to care for hepatitis C. 
  • Patient-care practices associated with an increased prevalence of hepatitis C virus infection among chronic hemodialysis patients. 
  • Patient-centered HCV care via telemedicine for individuals on medication for opioid use disorder: Telemedicine for Evaluation, Adherence and Medication for Hepatitis C (TEAM-C). 
  • Patient-reported outcomes 12 months after hepatitis C treatment with direct-acting antivirals: Results from the PROP UP study. 
  • Patient-reported symptoms during and after direct-acting antiviral therapies for chronic hepatitis C: The PROP UP study. 
  • Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. 
  • Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. 
  • PharmGKB summary: peginterferon-α pathway. 
  • Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus. 
  • Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. 
  • Poly(A)-binding protein is differentially required for translation mediated by viral internal ribosome entry sites. 
  • Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in North America. 
  • Positive serum cryoglobulin is associated with worse outcome after liver transplantation for chronic hepatitis C. 
  • Prediction of the Risk of Hepatocellular Carcinoma in Chronic Hepatitis C Patients after Sustained Virological Response by Aspartate Aminotransferase to Platelet Ratio Index. 
  • Prediction of treatment week eight response & sustained virologic response in patients treated with boceprevir plus peginterferon alfa and ribavirin. 
  • Predictors of consent to pharmacogenomics testing in the IDEAL study. 
  • Prevalence of non-A, non-B hepatitis/hepatitis C virus antibody in laboratory quality-assurance sera. 
  • Proteomic analysis of mitochondrial-associated ER membranes (MAM) during RNA virus infection reveals dynamic changes in protein and organelle trafficking. 
  • Proton pump inhibitor usage reduces sustained viral response rates for veterans with HIV/HCV coinfection on ledipasvir/sofosbuvir: a real-world study from a multicentre VA cohort. 
  • RNA interference and single particle tracking analysis of hepatitis C virus endocytosis. 
  • Real-World Effectiveness of DAA Therapies in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection: 996 Veterans Can't Be Wrong. 
  • Recurrent demyelinating myelitis associated with hepatitis C viral infection. 
  • Regulation of hepatic innate immunity by hepatitis C virus. 
  • Relationship of smoking and fibrosis in patients with chronic hepatitis C. 
  • Relationships between hepatic iron content and virologic response in chronic hepatitis C patients treated with interferon and ribavirin. 
  • Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. 
  • Reprogramming of cellular metabolic pathways by human oncogenic viruses. 
  • Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir Is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and -3 Clinical Trials. 
  • Risk factors for prevalent hepatitis C virus-infection among inmates in a state prison system in Mexico. 
  • Role of the asialoglycoprotein receptor in binding and entry of hepatitis C virus structural proteins in cultured human hepatocytes. 
  • Roles for endocytic trafficking and phosphatidylinositol 4-kinase III alpha in hepatitis C virus replication. 
  • Safety and antiviral activity of albinterferon alfa-2b dosed every four weeks in genotype 2/3 chronic hepatitis C patients. 
  • Safety and antiviral activity of albinterferon alfa-2b in prior interferon nonresponders with chronic hepatitis C. 
  • Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET. 
  • Seroconversion for hepatitis C virus antibody in bone marrow recipients treated with immune globulin. 
  • Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy. 
  • Sex and age differences in lipid response to chronic infection with the hepatitis C virus in the United States National Health and Nutrition Examination Surveys. 
  • Short and Long-Term Postoperative Complications Following Total Joint Arthroplasty in Patients With Human Immunodeficiency Virus, Hepatitis B, or Hepatitis C. 
  • Silent damage? Occult HCV replication and histological disease may occur following apparent HCV clearance. 
  • Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial. 
  • Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. 
  • Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. 
  • Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. 
  • Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. 
  • Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. 
  • Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. 
  • Specific polymorphisms in hepatitis C virus genotype 3 core protein associated with intracellular lipid accumulation. 
  • Standard Versus Extended Duration Direct-Acting Antiviral Therapy in Hepatitis C Patients With Slow Response to Treatment. 
  • Steatosis and chronic hepatitis C virus infection: mechanisms and significance. 
  • Steatosis is an independent predictor of relapse following rapid virologic response in patients with HCV genotype 3. 
  • Successful Re-treatment of Hepatitis C Virus in Patients Coinfected With HIV Who Relapsed After 12 Weeks of Ledipasvir/Sofosbuvir. 
  • Surveillance for hepatocellular carcinoma. 
  • Sustainable and equivalent improvements in symptoms and functional well-being following viral cure from ledipasvir/sofosbuvir versus elbasvir/grazoprevir for chronic hepatitis C infection: Findings from the randomized PRIORITIZE trial. 
  • Sustained viral response after interferon-based therapy in chronic hepatitis C: more evidence to support a life-long cure. 
  • Sustained virologic response rates with telaprevir-based therapy in treatment-naive patients evaluated by race or ethnicity. 
  • Systems biological analyses reveal the hepatitis C virus (HCV)-specific regulation of hematopoietic development. 
  • Telaprevir for previously treated chronic HCV infection. 
  • Telaprevir for previously untreated chronic hepatitis C virus infection. 
  • Telaprevir for the treatment of chronic hepatitis C infection. 
  • Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. 
  • Testing and Clinical Management of Health Care Personnel Potentially Exposed to Hepatitis C Virus - CDC Guidance, United States, 2020. 
  • The acidic domain of the hepatitis C virus NS4A protein is required for viral assembly and envelopment through interactions with the viral E1 glycoprotein. 
  • The clinical utility of using Catrimox-14-treated whole blood in detecting hepatitis C virus RNA. 
  • The face of future hepatitis C antiviral drug development: recent biological and virologic advances and their translation to drug development and clinical practice. 
  • The favorable IFNL3 genotype escapes mRNA decay mediated by AU-rich elements and hepatitis C virus-induced microRNAs. 
  • The hepatitis C crisis in the African American Community: findings and recommendations. 
  • The hepatitis C virus 3'-untranslated region or a poly(A) tract promote efficient translation subsequent to the initiation phase. 
  • The impact of HCV therapy in a high HIV-HCV prevalence population: A modeling study on people who inject drugs in Ho Chi Minh City, Vietnam. 
  • The impact of hepatitis C virus coinfection on HIV-related kidney disease: a systematic review and meta-analysis. 
  • The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. 
  • The mitochondrial targeting chaperone 14-3-3ε regulates a RIG-I translocon that mediates membrane association and innate antiviral immunity. 
  • The rapid evolution of treatment strategies for hepatitis C. 
  • Tight junction proteins claudin-1 and occludin control hepatitis C virus entry and are downregulated during infection to prevent superinfection. 
  • Transcriptional responses define dysregulated immune activation in Hepatitis C (HCV)-naïve recipients of HCV-infected donor kidneys. 
  • Transient CD86 expression on hepatitis C virus-specific CD8+ T cells in acute infection is linked to sufficient IL-2 signaling. 
  • Transplantation of hepatitis C-positive livers in hepatitis C-positive patients is equivalent to transplanting hepatitis C-negative livers. 
  • Treating HCV Infection: It Doesn't Get Much Better Than This. 
  • Treatment of HCV infection by targeting microRNA. 
  • Treatment of acute hepatitis C with interferon alfa-2b. 
  • Treatment of chronic hepatitis C in blacks and non-Hispanic whites. 
  • Treatment of genotype 1 HCV infection in the HIV coinfected patient in 2014. 
  • Treatment of hepatitis C in special populations. 
  • Two new ursane-type triterpenoid saponins from Elsholtzia bodinieri. 
  • Up-regulation of Hedgehog pathway is associated with cellular permissiveness for hepatitis C virus replication. 
  • Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2/3. 
  • Viral infection of human progenitor and liver-derived cells encapsulated in three-dimensional PEG-based hydrogel. 
  • Virologic response rates of weight-based taribavirin versus ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C. 
  • WTAP Targets the METTL3 m6A-Methyltransferase Complex to Cytoplasmic Hepatitis C Virus RNA to Regulate Infection. 
  • XRN1 stalling in the 5' UTR of Hepatitis C virus and Bovine Viral Diarrhea virus is associated with dysregulated host mRNA stability. 
• 

  Keywords of People

  • Choi, Steven Sok, Associate Professor of Medicine, Medicine, Gastroenterology
  • Horner, Stacy M., Associate Professor in Integrative Immunobiology, Duke Science & Society